Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.77
-0.15 (-2.53%)
Dec 5, 2025, 4:00 PM EST - Market closed
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
449.54M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SLDB News
- 4 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia - GlobeNewsWire
- 19 days ago - Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - GlobeNewsWire
- 25 days ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy - GlobeNewsWire
- 4 weeks ago - Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions - GlobeNewsWire
- 2 months ago - Solid Biosciences to Present at Upcoming Scientific Meetings - GlobeNewsWire
- 2 months ago - Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting - GlobeNewsWire